JP2007523207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007523207A5 JP2007523207A5 JP2007500151A JP2007500151A JP2007523207A5 JP 2007523207 A5 JP2007523207 A5 JP 2007523207A5 JP 2007500151 A JP2007500151 A JP 2007500151A JP 2007500151 A JP2007500151 A JP 2007500151A JP 2007523207 A5 JP2007523207 A5 JP 2007523207A5
- Authority
- JP
- Japan
- Prior art keywords
- depression
- disorder
- features
- disorders
- sleep
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 208000020401 Depressive disease Diseases 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 208000031091 Amnestic disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 206010007776 catatonia Diseases 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
Description
式（Ｉ）で示される化合物はまた、精神病、例えば、統合失調症、鬱病（本明細書において、精神病性特徴、緊張病性特徴、鬱病性特徴、非定型特徴もしくは産後発症を伴うかまたは伴わない、双極性鬱病、単極性鬱病、単発性もしくは反復性大鬱病エピソード、季節性情動障害、非定型特徴を伴うかまたは伴わない早発性または遅発性の気分変調障害、神経症鬱病および社会恐怖症、例えばアルツハイマー型の認知症に付随的な鬱病、鬱病型分裂情動性障害および心筋梗塞、糖尿病、流産または堕胎などを包含するがそれらに限定されるものではない一般的な医学的症状に起因する抑鬱性障害を包含するものとして使用される）、不安障害（汎発性不安障害および社会的不安障害を包含）、パニック障害、広場恐怖症、社会恐怖症、強迫性障害および心的外傷後ストレス障害、認知症、健忘性障害および年齢関連記憶障害を包含する記憶障害、神経性食欲不振症および神経性大食症を包含する摂食行動の障害、性的機能不全、睡眠障害（概日リズムの妨害、睡眠異常、不眠症、睡眠時無呼吸およびナルコレプシーを包含）、コカイン、エタノール、ニコチン、ベンゾジアゼピン、アルコール、カフェイン、フェンシクリジン（フェンシクリジン様化合物）、アヘン剤（例えば、ヘロイン、モルヒネ）、アンフェタミンまたはアンフェタミン関連薬物（例えば、デキストロアンフェタミン、メチルアンフェタミン）またはその組み合わせのような薬物の乱用からの離脱の治療においても有用であり得る。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403998A GB0403998D0 (en) | 2004-02-23 | 2004-02-23 | Compounds |
| GB0425071A GB0425071D0 (en) | 2004-11-12 | 2004-11-12 | Compounds |
| PCT/EP2005/001939 WO2005080350A1 (en) | 2004-02-23 | 2005-02-21 | Pyrimidine derivatives as cannabinoid receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007523207A JP2007523207A (ja) | 2007-08-16 |
| JP2007523207A5 true JP2007523207A5 (ja) | 2008-03-21 |
Family
ID=34889142
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007500151A Withdrawn JP2007523207A (ja) | 2004-02-23 | 2005-02-21 | カンナビノイド受容体モジュレーターとしてのピリミジン誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080261977A1 (ja) |
| EP (1) | EP1718620A1 (ja) |
| JP (1) | JP2007523207A (ja) |
| WO (1) | WO2005080350A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007707A1 (en) * | 2006-04-07 | 2008-12-31 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| AU2010231694A1 (en) | 2009-03-30 | 2011-10-06 | Astellas Pharma Inc. | Pyrimidine compound |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| KR20150119012A (ko) | 2013-02-08 | 2015-10-23 | 셀진 아빌로믹스 리서치, 인코포레이티드 | Erk 억제제 및 이의 용도 |
| WO2016025561A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Forms and compositions of an erk inhibitor |
| CN106146468B (zh) * | 2015-04-17 | 2020-12-01 | 杭州雷索药业有限公司 | 吡啶酮类蛋白激酶抑制剂 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| EP0850228A1 (en) * | 1995-09-01 | 1998-07-01 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| EP1534687B1 (en) * | 2002-08-21 | 2006-09-27 | Glaxo Group Limited | 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators |
| JP2009504769A (ja) * | 2005-08-16 | 2009-02-05 | ジェンザイム・コーポレーション | ケモカイン受容体結合化合物 |
-
2005
- 2005-02-21 US US10/597,521 patent/US20080261977A1/en not_active Abandoned
- 2005-02-21 JP JP2007500151A patent/JP2007523207A/ja not_active Withdrawn
- 2005-02-21 EP EP05715508A patent/EP1718620A1/en not_active Withdrawn
- 2005-02-21 WO PCT/EP2005/001939 patent/WO2005080350A1/en active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520539A5 (ja) | ||
| JP2007523206A5 (ja) | ||
| JP2008501758A5 (ja) | ||
| JP2007523207A5 (ja) | ||
| JP2003511434A (ja) | モノアミン再取込み阻害剤として有用な新規ビアリールエーテル誘導体 | |
| RU2008139481A (ru) | Новые 1,4-диаза-бицикло[3.2.2]нонил-оксадиазолильные производные и их медицинское применение | |
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| US20050119252A1 (en) | Ligands of melanocortin receptors and compositions and methods related thereto | |
| WO2007099423A1 (en) | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists | |
| RU2010119560A (ru) | Замещенные n-фенилбипирролидинкарбоксамиды и их терапевтическое применение | |
| JP2013540794A (ja) | 疼痛、精神病性障害、認知障害、またはアルツハイマー病の治療のためのアルファ‐７ニコチン性受容体修飾薬 | |
| BR122017023795B8 (pt) | método para preparação de composição farmacêutica | |
| MXPA06014919A (es) | Derivados de cicloamino 1,3-sustituido y su uso como antagonitas del receptor de histamina-3. | |
| JP2008543782A (ja) | ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト | |
| EA200970310A1 (ru) | Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht | |
| RU2009136330A (ru) | Тетрагидроизохинолиновые соединения в качестве модуляторов гистаминового н3 рецептора | |
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| KR20070086598A (ko) | 아릴- 및 헤테로아릴-치환 테트라히드로이소퀴놀린과노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 이의 용도 | |
| JP2007529495A5 (ja) | ||
| RU2008148941A (ru) | 4-[(3-фторфенокси)фенилметил]пиперидин метансульфонат, применение, способ синтеза и фармацевтические композиции | |
| IL198926A0 (en) | Compounds with a combination of cannabinoid-cb1 antagonism and acetylcholinesterase inhibition | |
| JP2007520537A5 (ja) | ||
| DK2614824T3 (en) | TRIAZOLD DERIVATIVES TO USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA | |
| JP2010514682A5 (ja) | ||
| JP2008503560A (ja) | ジアザビシクロ系のヒスタミン−３受容体アンタゴニスト |